Richard Koya, MD, PhD of Roswell Park Cancer Institute explains how the new data on T-Cell receptors impacts next generation for immunotherapies. He argues how the harnessing of t-cell receptors to recognize cancer cells will benefit future clinical trials. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.